ѧÊõÌÃÊ×Ò³ | ÎÄÏ×ÇóÖúÂÛÎÄ·¶ÎÄ | ÂÛÎÄÌâÄ¿ | ²Î¿¼ÎÄÏ× | ¿ªÌⱨ¸æ | ÂÛÎĸñʽ | ÕªÒªÌá¸Ù | ÂÛÎÄÖÂл | ÂÛÎIJéÖØ | ÂÛÎÄ´ð±ç | ÂÛÎÄ·¢±í | ÆÚ¿¯ÔÓÖ¾ | ÂÛÎÄд×÷ | ÂÛÎÄPPT
ѧÊõÌÃרҵÂÛÎÄѧϰƽ̨Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ҽѧÂÛÎÄ > »ù´¡Ò½Ñ§ÂÛÎÄ > Ò©ÀíѧÂÛÎÄ

ijҽԺסԺ»¼ÕßʹÓðÂÇúëĵĺÏÀíÐÔ̽¾¿

À´Ô´£ºÖйúÒ©Òµ ×÷Õߣº³ÌÍôÇÚ.
·¢²¼ÓÚ£º2021-08-13 ¹²4331×Ö

¡¡¡¡Õª    Òª£º¡¡Ä¿µÄ ̽ÌÖ°ÂÇúëÄÁÙ´²Ó¦ÓõĺÏÀíÐÔ¡£·½·¨ ѡȡҽԺ2019Äê9ÔÂÖÁ12ÔÂʹÓðÂÇúëĵÄסԺ»¼ÕߵIJ¡Àú70·Ý£¬Í³¼Æ°ÂÇúëĵÄÓÃÒ©ÊÊÓ¦Ö¤¡¢Ó÷¨ÓÃÁ¿¡¢ÓÃÒ©ÁƳ̡¢ÁªºÏÓÃÒ©¡¢Ò©Æ·²»Á¼·´Ó¦(ADR)µÈÇé¿ö£¬²¢·ÖÎöÓÃÒ©ºÏÀíÐÔ¡£½á¹û ËùÑ¡²¡ÀúÖаÂÇúëĵÄÓÃÒ©ÊÊÓ¦Ö¤ÒÔÏû»¯µÀ³öѪ¡¢¼±ÐÔÒÈÏÙÑס¢³¦¹£×èΪÖ÷£¬¼ÁÁ¿Îª0.1¡«0.8 mg/d£¬ÁƳÌΪ1¡«15 d£¬Ö÷ÒªÓëÖÊ×Ó±ÃÒÖÖÆ¼Á(42Àý)ÁªÓÃ;ÓÃÒ©ÆÚ¼äδ³öÏÖADR¡£²»¹æ·¶¡¢²»ºÏÀíÓÃÒ©¹²7Àý£¬Ö÷ҪΪÎÞÖ¸Õ÷ÓÃÒ©¡¢ÓÃÒ©ÁƳ̲»ÊÊÒ˵ȡ£½áÂÛ ¸ÃÔº°ÂÇúëĵÄÁÙ´²Ó¦ÓôæÔÚÒ»¶¨²»ºÏÀíÐÔ£¬Ðè³ÖÐø¸Ä½ø¡£

¡¡¡¡¹Ø¼ü´Ê :     °ÂÇúëÄ;ÁÙ´²Ó¦ÓÃ;ÓÃÒ©·ÖÎö;ºÏÀíÓÃÒ©;

¡¡¡¡Abstract£º¡¡Objective To investigate the rationality of the clinical application of octreotide. Methods A total of 70 medical records of inpatients treated with octreotide in our hospital from September to December 2019 were selected. The indications,usage and dosage,course of treatment,combination medication and adverse drug reactions( ADR) of octreotide were analyzed,and the rationality of medication was analyzed. Results The medication indications of octreotide were gastrointestinal bleeding,acute pancreatitis and intestinal obstruction. The dosage of octreotide was 0. 1-0. 8 mg/d with a treatment course of 1-15 d,mainly combined with proton pump inhibitors( 42 cases). There was no ADR during the medication. There were 7 cases of irregular and irrational medication,mainly including medication without indication and inappropriate treatment course. Conclusion The clinical application of octreotide in our hospital is unreasonable and needs continuous improvement.

¡¡¡¡Keyword£º¡¡octreotide; clinical application; medication analysis; rational medication;

¡¡¡¡°ÂÇúëÄΪÈ˹¤ºÏ³ÉµÄÌìÈ»Éú³¤ÒÖËØµÄ°ËëÄ»·×´»¯ºÏÎ¾ßÓÐÒÖÖÆÉú³¤¼¤ËØ¡¢´Ù¼××´ÏÙËØ¡¢Î¸³¦µÀºÍÒÈÄÚ·ÖÃÚ¼¤Ëز¡ÀíÐÔ·ÖÃÚ¹ý¶à£¬ÒÖÖÆÒÈø¡¢ÒȸßѪÌÇËØºÍÒȵºËØ·ÖÃڵȶàÖÖÉúÀí»îÐÔ£¬ÒÖÖÆÎ¸Ëᡢθµ°°×øºÍθÃÚËØ·ÖÃÚ£¬¸ÄÉÆÎ¸ð¤Ä¤ÑªÁ÷¹©Ó¦£¬´Ù½øð¤Ä¤µÄÐÞ¸´£¬ÁÙ´²ÓÃÓÚÖÎÁÆÓ¦¼¤ÐÔÀ£ÑñºÍÏû»¯ÐÔÀ£ÑñÒýÆðµÄ賦µÀ´ó³öѪ[1]¡£°ÂÇúëĵÄÁÙ´²ÊÊÓ¦Ö¤¹ã£¬Îª´Ù½øÁÙ´²¹æ·¶¡¢ºÏÀíÓ¦Ó㬱¾Ñо¿ÖлعËÐÔ·ÖÎöÁËÎÒԺסԺ»¼Õß°ÂÇúëĵÄʹÓÃÇé¿ö£¬ÎªÁÙ´²ºÏÀíÓÃÒ©Ìṩ²Î¿¼¡£ÏÖ±¨µÀÈçÏ¡£

¡¡¡¡1 ¡¢×ÊÁÏÓë·½·¨

¡¡¡¡Ëæ»úѡȡÎÒÔºÒ½ÔºÐÅϢϵͳÖÐ2019Äê9ÔÂÖÁ12ÔÂʹÓðÂÇúëĵÄסԺ»¼ÕߵIJ¡Àú70·Ý£¬²ÎÕÕ°ÂÇúëÄҩƷ˵Ã÷Êé¡¢¡¶³ÂÐÂǫбàÒ©Îïѧ(µÚ18°æ)¡·[1]¡¢Ïà¹ØÖ¸ÄÏÓëÎÄÏ×ÖÆ¶©°ÂÇúëÄÁÙ´²Ó¦Óõ÷²é±í¡£µ÷²é±íÄÚÈݰüÀ¨»¼Õß»ù±¾ÐÅÏ¢¡¢ÓÃÒ©ÊÊÓ¦Ö¤¡¢Ó÷¨ÓÃÁ¿¡¢ÓÃÒ©ÁƳ̡¢ÁªºÏÓÃÒ©¡¢Ò©Æ·²»Á¼·´Ó¦(ADR)µÈÐÅÏ¢£¬ÒÔÆÀ¼Û°ÂÇúëÄÁÙ´²Ó¦ÓõĺÏÀíÐÔ¡£

1.png

¡¡¡¡2¡¢ ½á¹û

¡¡¡¡2.1¡¢ »¼Õß»ù±¾ÐÅÏ¢

¡¡¡¡70Àý»¼ÕßÖУ¬ÄêÁä15¡«88Ë꣬ƽ¾ù62Ëê;ÄÐ47Àý£¬Å®23Àý;¹²ÓÐ9¸öÁÙ´²¿ÆÊÒʹÓðÂÇúëÄ£¬ÆäÖÐÏû»¯ÄÚ¿Æ30Àý£¬Î¸³¦Íâ¿Æ17Àý¡£Ïê¼û±í1¡£

¡¡¡¡±í1 70·Ý²¡ÀúÖÐʹÓðÂÇúëĵÄÁÙ´²¿ÆÊÒ¼°»¼ÕßÐÔ±ðÇé¿ö

GetImg (1).jpg

¡¡¡¡2.2 ¡¢ÊÊÓ¦Ö¤

¡¡¡¡70Àý»¼ÕßÖУ¬¹²Éæ¼°12ÖÖÓÃÒ©Ö¸Õ÷£¬°üÀ¨Ïû»¯µÀ³öѪ31Àý¡¢¼±ÐÔÒÈÏÙÑ×15Àý¡¢³¦¹£×è16ÀýµÈ¡£ÆäÖУ¬·ûºÏÓÃÒ©Ö¸Õ÷17Àý(24.29%)£¬³¬Ò©Æ·ËµÃ÷ÊéÓÃÒ©46Àý(65.71%)¡£²»¹æ·¶¡¢²»ºÏÀíÓÃÒ©7Àý(10.00%)£¬Ö÷ҪΪÎÞÖ¸Õ÷ÓÃÒ©¡¢ÓÃÒ©ÁƳ̲»ÊÊÒ˵ȡ£Ïê¼û±í2¡£

¡¡¡¡2.3 ¡¢Ó÷¨ÓÃÁ¿

¡¡¡¡70Àý»¼ÕßÖУ¬³ÖÐø¾²Âö±Ã×¢44Àý£¬Æ¤ÏÂ×¢Éä26Àý£¬ÈܼÁ¾ùΪ0.9%ÂÈ»¯ÄÆ×¢ÉäÒº;²»Í¬ÓÃÒ©Ö¸Õ÷µÄÓÃÁ¿ÓвîÒ죬0.1 mg/d 1Àý£¬0.3 mg/d 31Àý£¬0.45 mg/d 7Àý£¬0.6 mg/d 30Àý£¬0.8 mg/d 1Àý;ÓÃÒ©ÁƳÌΪ1¡«15 d£¬ÒÔ¸¹Í´ºÍ¸¹ÕÍ»º½â¡¢¿É½øÊ³Á÷ÖÊÒûʳ¡¢Î¸³¦µÀÖ¢×´¸ÄÉÆ¼°ºÃתΪͣҩָÕ÷¡£Ïê¼û±í2¡£

¡¡¡¡2.4¡¢ ÁªºÏÓÃÒ©ÓëADR

¡¡¡¡70Àý»¼ÕßÖУ¬ÁªÓÃÖÊ×Ó±ÃÒÖÖÆ¼Á42Àý(60.00%)¡£ÆäÖУ¬ÁªºÏÓÃÓÚÏû»¯µÀ³öѪ27Àý(38.57%)£¬¼±ÐÔÒÈÏÙÑ×8Àý(11.43%)£¬³¦¹£×è7Àý(10.00%)¡£ÓÃÒ©ÆÚ¼ä¾ùδ·¢ÏÖADR¡£

¡¡¡¡3 ¡¢ÌÖÂÛ

¡¡¡¡3.1 ¡¢³¬Ò©Æ·ËµÃ÷ÊéÓÃÒ©ºÍÎÞÖ¸Õ÷ÓÃÒ©ÏÖÏóÃ÷ÏÔ

¡¡¡¡°ÂÇúëÄ×¢ÉäҺҩƷ˵Ã÷ÊéÅú×¼µÄÊÊÓ¦Ö¤°üÀ¨¸ÎÓ²»¯ËùÖÂʳµÀθµ×¾²ÂöÇúÕųöѪµÄ½ô¼±ÖÎÁÆ£¬»º½âÓë賦ÒÈÄÚ·ÖÃÚÖ×ÁöÓйصÄÖ¢×´ÓëÌåÕ÷£¬Ô¤·ÀÒÈÏÙÊõºó²¢·¢Ö¢ºÍÖ«¶Ë·Ê´óÖ¢¡£±¾Ñо¿ÖУ¬½ö17Àý»¼ÕßµÄÊÊÓ¦Ö¤·ûºÏ°ÂÇúëĵÄÓÃÒ©ÊÊÓ¦Ö¤£¬46Àý³¬Ò©Æ·ËµÃ÷ÊéÓÃÓÚ¼±ÐÔÒÈÏÙÑס¢³¦¹£×èµÈ¼²²¡µÄ·ÀÖΡ£

¡¡¡¡±í2 »¼ÕßÓÃÒ©Ö¸Õ÷¼°Ó÷¨ÓÃÁ¿(n=70)

GetImg (2).jpg

¡¡¡¡Ïû»¯µÀ³öѪÊÇÏû»¯µÀÖ×ÁöµÄÖ÷ÒªÁÙ´²±íÏÖ»òÊ×·¢Ö¢×´¡£¾²ÂöµÎ×¢Éú³¤ÒÖËØ¼°ÀàËÆÎïÁªºÏÖÊ×Ó±ÃÒÖÖÆ¼Á¶ÔÖ×ÁöÐÔ³öѪºÍ¼±ÐÔθð¤Ä¤ËðÉËÓÐЧ[2];¶ÔÓÚ²»Ã÷Ô­Òò¼±ÐÔÏû»¯µÀ³öѪ£¬¿É¾²Âö±Ã×¢ÖÊ×Ó±ÃÒÖÖÆ¼ÁÁªÓÃÉú³¤ÒÖËØ»òÆäÀàËÆÎïÖÎÁÆ£¬²¡ÒòÃ÷È·ºóÔÙµ÷ÕûÓÃÒ©[3]¡£ÄÚ¾µÏÂÖÎÁÆ»òÍâ¿ÆÖÎÁÆÎÞЧµÄÒòÏû»¯µÀѪ¹Ü·¢Óý²»Á¼¶ø³öѪ»¼ÕßʹÓðÂÇúëÄÖÎÁÆ£¬¿É½µµÍÊäѪƵÂÊ£¬ÇÒÖÎÁÆÄÑÖÎÐÔС³¦Ñª¹Ü·¢Óý²»Á¼³öѪÁÆÐ§½ÏºÃ[4]¡£±¾Ñо¿ÖаÂÇúëÄÓÃÓÚʳ¹Üθµ×¾²ÂöÇúÕÅÆÆÁѳöѪ13Àý£¬Ïû»¯ÐÔÀ£Ññ°é³öѪ6Àý£¬¶ñÐÔÖ×Áö°éÏû»¯µÀ³öѪ8Àý£¬²»Ã÷Ô­ÒòÏû»¯µÀ³öѪ4Àý£¬¸øÒ©ºó³öѪ֢״¾ùºÃת£¬ÎÞÑÏÖØ²¢·¢Ö¢¡£

¡¡¡¡¡¶Öйú¼±ÐÔÒÈÏÙÑ×ÕïÖÎÖ¸ÄÏ(2019ÉòÑô)¡·Ö¸³ö£¬°ÂÇúëÄ¿Éͨ¹ýÖ±½ÓÒÖÖÆÒÈÏÙÍâ·ÖÃÚ¶ø·¢»Ó×÷Ó㬶ÔÔ¤·ÀERCPÊõºóÒÈÏÙÑ×Ò²Óлý¼«×÷ÓÃ[5]¡£°ÂÇúëĸ¨Öú³£¹æÖÎÁÆÇáÐÍ/ÖØÖ¢¼±ÐÔÒÈÏÙÑ×£¬ÁÙ´²ÁÆÐ§ºÃ£¬¿ÉÏÔןÄÉÆÑªÒºÁ÷±äѧָ±ê¼°ÑªÇåÑ×ÐÔÒò×Óˮƽ£¬ÓÐЧ½µµÍѪÇåµí·Ûøˮƽ£¬¸ÄÉÆÔ¤ºó£¬¼õÉÙ²¢·¢Ö¢[6,7]¡£±¾Ñо¿ÖУ¬°ÂÇúëÄÓÃÓÚ¼±ÐÔÒÈÏÙÑ×15Àý£¬ÆäÖÐÖÐÖØ¶ÈÒÈÏÙÑ×10Àý¡¢ÇáÖ¢ÒÈÏÙÑ×5Àý£¬ÁÙ´²¾ùÔçÆÚÓ¦ÓðÂÇúëÄÒÖÖÆÒÈø·ÖÃÚ£¬¸¹Í´Ã÷ÏÔ»º½â£¬Ñ×ÐÔÖ¸±ê¸ÄÉÆ£¬ÌáʾÖÎÁÆÓÐЧ¡£

¡¡¡¡³¦¹£×èÊÇÒ»ÖÖ±È½ÏÆÕ±éµÄ¼±¸¹Ö¢£¬°ÂÇúëÄ¿Éͨ¹ý¼õÉÙ賦µÀÏÙÌå·ÖÃÚ¼°ÄÚÔàѪÁ÷Á¿£¬¼õÇ᳦¹£×軼Õߵĸ¹ÕÍ¡¢¸¹Í´Ö¢×´£¬ÓÐЧ¸ÄÉÆÎ¸³¦µÀ¹¦ÄÜ£¬ÓÅÓÚ¿¹µ¨¼îÀàÒ©ÎÁªºÏ³£¹æÖÎÁÆÓÃÓÚ³¦¹£×è¿ÉÌá¸ßÁÆÐ§¡¢¸ÄÉÆÖ¢×´£¬¼õÉÙ²»Á¼·´Ó¦[8,9,10]¡£±¾Ñо¿ÖУ¬°ÂÇúëÄÓÃÓÚ³¦¹£×è16Àý£¬ÆäÖÐ賦µÀÖ×ÁöÊõºó°é³¦¹£×è8Àý£¬ÓÃÒ©ºó£¬¸¹Í´¡¢¸¹ÕÍÖ¢×´¾ùÃ÷ÏÔ»º½â£¬¸¹²¿Ñ¹Í´·¶Î§ËõС£¬¸ØÃŻָ´ÅÅÆøÅű㣬ÇÒδ¼û°ÂÇúëÄÏà¹ØADR¡£

¡¡¡¡²ÎÕÕ°ÂÇúëÄҩƷ˵Ã÷Êé¡¢¹úÄÚÍâÁÙ´²Ö¸Äϼ°Ïà¹ØÎÄÏ×£¬ÎÞÖ¸Õ÷ÓÃÒ©3Àý¡£1ÀýÕï¶ÏΪ¸ÎÓ²»¯¡¢Æ¢´óµÄ»¼Õߣ¬Ðв¿·ÖÆ¢¶¯Âö˨ÈûÖÎÁÆ£¬ÊõºóÎÞÃ÷ÏÔ²»ÊÊ£¬¸øÓè°ÂÇúëÄÒÖËáÖÎÁÆ£¬ÎÞÃ÷È·ÓÃÒ©Ö¸Õ÷;ÁíÓÐ2Àý賦µÀÖ×Áö»¼ÕßÎÞ¶ñÐÄŻ͡¢¸¹ÐººÚ±ãµÈ£¬ÁÙ´²Ó¦ÓðÂÇúëÄ´Ù½ø³¦µÀÈ䶯£¬Ô¤·À³¦¹£×èµÄ·¢Éú£¬ÎÞÃ÷È·ÓÃÒ©Ö¸Õ÷¡£

¡¡¡¡3.2¡¢ Ó÷¨ÓÃÁ¿Ó¦·ûºÏҩƷ˵Ã÷ÊéÍÆ¼ö

¡¡¡¡°ÂÇúëij£ÓøøÒ©Í¾¾¶ÓÐÖ±½Ó¾²ÂöµÎ×¢¡¢Æ¤ÏÂ×¢É估΢Á¿ÊäÒº±Ã¾²ÂöµÎ×¢¡£±¾Ñо¿ÖУ¬³ÖÐø¾²Âö±Ã×¢44Àý£¬Æ¤ÏÂ×¢Éä26Àý¡£²»Í¬¸øÒ©·½Ê½È¡µÃµÄÁÆÐ§²»Í¬£¬³ÖÐøÎ¢Á¿ÊäÒº±Ã²»½öÄܵ÷½Ú¸øÒ©ËÙ¶È£¬ÓÃÒ©¼ÁÁ¿¸ü¾«×¼£¬ÔÚ±£Ö¤ÑªÒ©Å¨¶ÈµÄͬʱ£¬»¹ÄܼõÉÙ¸øÒ©´ÎÊý;ÄÜÔÚ¶Ìʱ¼äÄÚÓÐЧ¿ØÖÆÊ³¹Üθµ×¾²ÂöÇúÕÅÆÆÁѳöѪ֢״£¬ÖÎÁƼ±ÐÔÒÈÏÙÑס¢³¦¹£×èÓÅÊÆÃ÷ÏÔ[11]¡£Ò©Æ·ËµÃ÷ÊéÍÆ¼ö°ÂÇúëĵijõʼ¼ÁÁ¿Îª0.05¡«0.10 mg/d£¬×î´ó¼ÁÁ¿²»³¬¹ý1.5 mg/d£¬Ò»°ã¼ÁÁ¿·¶Î§Îª0.05¡«1.20 mg/d£¬±¾Ñо¿°ÂÇúëĵÄÓÃÒ©¼ÁÁ¿·¶Î§Îª0.1¡«0.8 mg/d£¬ÓëҩƷ˵Ã÷ÊéÍÆ¼ö¼ÁÁ¿·¶Î§Ò»Ö¡£

¡¡¡¡3.3 ¡¢ÁƳ̲»Ò»

¡¡¡¡°ÂÇúëÄÓÃÓÚʳ¹Üθ¾²ÂöÇúÕÅÆÆÁѳöѪ¡¢Î¸³¦ÒÈÄÚ·ÖÃÚÖ×Áö¡¢Ô¤·ÀÒÈÏÙÊõºó²¢·¢Ö¢¡¢Ö«¶Ë·Ê´óÖ¢µÈÊÊÓ¦Ö¤¾ùÓÐÃ÷È·µÄÁƳ̣¬ÆäÓà¾ùÒÔÁÙ´²Ö¢×´ºÃת×÷Ϊͣҩָ±ê¡£¿É¼û£¬°ÂÇúëĵÄÓÃÒ©ÁƳ̲»Ò»¡£¼±ÐÔÒÈÏÙÑ×»¼ÕßÖ±µ½ÁÙ´²Ö¢×´Ïûʧ¡¢ÑªÄòµí·Ûø»Ö¸´Õý³£Ë®Æ½²ÅÍ£Óã¬Ò»°ãΪ10 d[12]¡£±¾Ñо¿ÖУ¬15Àý¼±ÐÔÒÈÏÙÑ×ÖУ¬5ÀýÁƳÌ1¡«3 d,6Àý4¡«7 d,3Àý8¡«9 d,1Àý15 d£¬ÓÃÒ©ÁƳÌÓëÎÄÏ×[10]µÄ±¨µÀ»ù±¾Ïà·û;13ÀýÏû»¯µÀ³öѪÖУ¬11ÀýÓÃÒ©ÁƳ̲»³¬¹ý5 d£¬ÁƳ̹淶£¬2Àý³öѪ»¼Õߣ¬ÁƳÌΪ7 d£¬ÁÆ³ÌÆ«³¤£¬µ«»¼Õß³öѪÁ¿½Ï´ó£¬¼Ì·¢Ê§ÑªÐÔÐݿˣ¬¿É×ÃÇéÑÓ³¤ÁƳÌ;3ÀýÓÃÓÚÔ¤·ÀERCPÊõºó²¢·¢Ö¢ÖУ¬½öÊ×´ÎÆ¤ÏÂ×¢Éä0.1 mg£¬ÊõºóʹÓÃ1¡«3 d£¬µ«ÆäÓÃÓÚÔ¤·ÀÒÈÏÙÊõºó²¢·¢Ö¢Ê±ÒªÇó³ÖÐøÖÎÁÆ7 d£¬ÁƳÌÃ÷ÏÔ²»×ã;1ÀýθÀ£Ññ°éÏû»¯µÀ³öѪÖУ¬Êõºó»Ö¸´Á¼ºÃ£¬ÎÞ¸¹Í´¡¢Å»Ñª¡¢±ãѪ£¬Ö¹Ñªºó¼ÌÐøÊ¹Óã¬ÓÃÒ©ÁƳÌΪ9 d£¬ÁÆ³ÌÆ«³¤¡£ÁƳ̹ý¶Ì´ï²»µ½ÖÎÁÆÐ§¹û£¬ÁƳ̹ý³¤¿ÉÄÜ»áÔö¼ÓADRµÄ·¢Éú·çÏÕ¡£

¡¡¡¡3.4 ¡¢ÁªºÏÓÃÒ©¼°°²È«ÐÔ·ÖÎö

¡¡¡¡°ÂÇúëij£ÁªºÏÖÊ×Ó±ÃÒÖÖÆ¼ÁÓÃÓÚÏû»¯µÀ³öѪ¡¢¼±ÐÔÒÈÏÙÑס¢Õ³Á¬ÐÔ³¦¹£×èµÈÏû»¯ÏµÍ³Ïà¹Ø¼²²¡¡£Meta·ÖÎö±íÃ÷£¬°ÂÇúëÄÁªºÏÖÊ×Ó±ÃÒÖÖÆ¼ÁÖÎÁÆÉÏÏû»¯µÀ³öѪЧ¹ûÓÅÓÚµ¥ÓÃÖÊ×Ó±ÃÒÖÖÆ¼Á£¬Äܸü¿ì¡¢¸üÓÐЧµØÖ¹Ñª[13]£¬°²È«ÐÔºÃ[14]¡£±¾Ñо¿ÖУ¬42Àý»¼ÕßÁªÓÃÁËÖÊ×Ó±ÃÒÖÖÆ¼Á£¬¸¹Í´¡¢¸¹Õ͸ÐÃ÷ÏÔ»º½â£¬Î´Å»Ñª¡¢ºÚ±ã£¬²¡ÇéºÃת¡£

¡¡¡¡ÓйذÂÇúëÄADR±¨µÀ½ÏÉÙ£¬Ö÷ÒªADRΪÓÃÒ©²¿Î»²»ÊʺÍ賦µÀ·´Ó¦£¬½Ï¶Ìʱ¼äÄÚ¾ù¿É×ÔÐкÃת¡£ÓÉÓÚ°ÂÇúëÄ¿ÉÄÜÒýÆðѪÌǵ÷½ÚÎÉÂÒ£¬Ó¦¼à²âѪÌÇˮƽ£¬ÒÔÃâ·¢Éú²»Á¼ºó¹û[15]¡£±¾Ñо¿ÖÐδ·¢ÏÖADR£¬Ìáʾ°ÂÇúëÄÁÙ´²Ó¦Óð²È«ÐԽϺá£

¡¡¡¡3.5 ¡¢Ð¡½á

¡¡¡¡¸ÃÔº°ÂÇúëÄÁÙ´²Ó¦Óûù±¾ºÏÀí£¬µ«³¬ËµÃ÷ÊéÏÖÏó¶à·¢¡£³¬ËµÃ÷ÊéÓÃÒ©²¢·Ç²»ºÏÀíÓÃÒ©£¬Ò½ÁÆ»ú¹¹Ó¦Öƶ©ÓëÒ½ÁÆÐÐΪÏàÊÊÓ¦µÄ³¬ËµÃ÷ÊéÓÃÒ©¹ÜÀí¹æ¶¨£¬¹æ·¶³¬ËµÃ÷ÊéÓÃÒ©ÐÐΪ¡£½¨Ò鿪չÊÊÓ¦Ö¤Ò©ÎïÁÙ´²Ñо¿£¬ºÏÀí¡¢ºÏ¹æÍØÕ¹Ò©ÎïÊÊÓ¦Ö¤£¬ÒÔ±£Ö¤»¼ÕßÓÃÒ©°²È«¡¢ÓÐЧ¡¢¾­¼Ã¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡[1]³ÂÐÂÇ«£¬ ½ðÓÐÔ¥,ÌÀ¹â.³ÂÐÂǫбàÒ©Îïѧ(µÚ18°æ)M] .±±¾©:ÈËÃñÎÀÉú³ö°æÉç, 2018:608- 609.

¡¡¡¡[2]ÖÜÈÙ±ó£¬ÁÖÁØ. ¼±ÐÔÉÏÏû»¯µÀ³öѪ¼±ÕïÕïÖÎÁ÷³Ìר¼Ò¹²Ê¶(ÐÞ¶©¸å)µÄ²ûÊÍ[] .ÖйúÈ«¿ÆÒ½Ñ§, 2015,18(33):4021-4024.

¡¡¡¡[3]Ðì¾ü,´÷¼ÑÔ­,Òü·.¼±ÐÔÉÏÏû»¯µÀ³öѪ¼±ÕïÕïÖÎÁ÷³Ìר¼Ò¹²Ê¶[J] .Öйú¼±¾Èҽѧ£¬2021.41(1):1-10.

¡¡¡¡[4]ÌÀÃúêÅ,¸êÖ®ï£.²»Ã÷Ô­ÒòÏû»¯µÀ³öѪµÄ´¦Àí½øÕ¹ºÍÌôÕ½[J] .賦²¡Ñ§, 2018,23(8):449-454.

¡¡¡¡[5]¶ÅÞÈÆæ,³ÂÆä¿ü,Àîºê×Ö,µÈ.Öйú¼±ÐÔÒÈÏÙÑ×ÕïÖÎÖ¸ÄÏ(2019Äê,ÉòÑô)[J .ÁÙ´²¸Îµ¨²¡ÔÓÖ¾, 2019,35(12):2706-2711.

¡¡¡¡[6]Áõ°î¹ú,ÀîÃ÷´º,¸¶ËÉÁÖ.°ÂÇúëĸ¨ÖúÖÎÁƼ±ÐÔÒÈÏÙÑ×ÁÙ´²Ð§¹û¶Ô±È¹Û²ì[J] .ÈËÃñ¾üÒ½, 2020,63(4):375-378.

¡¡¡¡[7]»Æ½¨¹â.°ÂÇúëÄÖÎÁÆÇáÖ¢¼±ÐÔÒÈÏÙÑ×µÄÁÙ´²ÁÆÐ§[J] .ÁÙ´²ºÏÀíÓÃÒ©ÔÓÖ¾£¬2020, 13(28):26-27.

¡¡¡¡[8]Ðí¼Ñ࣬Áº±ûǬ,¹ù½¨.°ÂÇúëÄÁªºÏ³£¹æÖÎÁÆÓÃÓÚ»º½â¶ñÐÔ³¦¹£×èÓÐЧÐÔÓ밲ȫÐÔµÄMeta·ÖÎö[J].ÖйúÒ©·¿£¬ 2019,30(22):3138-3143.

¡¡¡¡[9]ÍõΡ,Çñ·ã,ÌÆÁú.´×Ëá°ÂÇúëÄÁªºÏ°ÂɳÀû²¬ÖÎÁÆÕ³Á¬ÐÔ³¦¹£×èÁÙ´²Ð§¹û¹Û²ì[J] .ÁÙ´²¾üÒ½ÔÓÖ¾, 2020.48(4)44-443.

¡¡¡¡[10]¶¡ÓÀ»Ô.°ÂÇúëÄÖÎÁƳ¦¹£×è50ÀýJ] .ÖйúÒ©Òµ, 2012,21(21)-:107-108.

¡¡¡¡[11]³Â¾²·æ,³Âº£Ñà¡£ ³ÂÑ©ÑµÈ.°ÂÇúëIJ»Í¬¸øÒ©·½Ê½ÖÎÁƼ±ÐÔÒÈÏÙÑ×ÁÙ´²Ð§¹ûMeta·ÖÎö[J].°²»ÕÒ½Ò© , 2020 ,24(2):402-408.

¡¡¡¡[12]Íõ¿ü,÷Üç.°ÂÇúëÄÔÚÆÕÍâ¿ÆµÄÁÙ´²Ó¦Óü°½øÕ¹[J] .ÐÄѪ¹ÜÍâ¿ÆÔÓÖ¾µç×Ó°æ, 2018,7(1):191.

¡¡¡¡[13]ºú¹ðÓ¢,Óౣƽ. °ÂÇúëÄÁªºÏÖÊ×Ó±ÃÒÖÖÆ¼ÁÖÎÁƷǾ²ÂöÇúÕÅÐÔÉÏÏû»¯µÀ³öѪµÄMeta·ÖÎö[J] .賦²¡Ñ§ºÍ¸Î²¡Ñ§ÔÓÖ¾£¬2015,24(12): 1479-1484.

¡¡¡¡[14]ÔøÎª³Û.°ÂÃÀÀ­ßòÁªºÏ°ÂÇúëÄÖÎÁƸÎÓ²»¯ÉÏÏû»¯µÀ³öѪµÄЧ¹ûÓ밲ȫÐÔÓÅÊÆ·ÖÎö[J] .¼ªÁÖҽѧ£¬ 2021,42(1):135-137.

¡¡¡¡[15]ÍõÄÈ£¬Íõº£ÌΣ¬ÑîöÎ.°ÂÇúëÄËùÖµÍѪÌÇ·çÏյĻعËÐÔÑо¿[J] . ʵÓÃÒ©ÎïÓëÁÙ´², 2021,24(1):82-84.


×÷Õßµ¥Î»£º°²»ÕÒ½¿Æ´óѧ¸½Êô°²ÇìҽԺҩʹÜÀí¿Æ
Ô­Îijö´¦£º³ÌÍôÇÚ.ijԺ°ÂÇúëÄÁÙ´²Ó¦ÓúÏÀíÐÔ·ÖÎö[J].ÖйúÒ©Òµ,2021,30(15):125-127.
Ïà¹Ø±êÇ©£º
  • ±¨¾¯Æ½Ì¨
  • ÍøÂç¼à²ì
  • ±¸°¸ÐÅÏ¢
  • ¾Ù±¨ÖÐÐÄ
  • ´«²¥ÎÄÃ÷
  • ³ÏÐÅÍøÕ¾